D. WESTERN THERAPEUTICS INSTITUTE, INC. Translation
Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.
Summary of Consolidated Financial Results
for the Year Ended December 31, 2021
(Based on Japanese GAAP)
February 10, 2022 | |||||
Company name: | D.Western Therapeutics Institute, Inc. | ||||
Stock exchange listing: | Tokyo | ||||
Stock code: | 4576 | URL https://www.dwti.co.jp | |||
Representative: | President and CEO | Yuichi Hidaka | |||
Inquiries: | Director and General Administration | Tetsuya Kawakami | TEL 052-218-8785 | ||
Division Manager | |||||
Scheduled date of ordinary general meeting of shareholders: | March 29, 2022 | ||||
Scheduled date to file Securities Report: | March 29, 2022 | ||||
Scheduled date to commence dividend payments: | - | ||||
Preparation of supplementary material on financial results: | Yes | ||||
Holding of financial results meeting: | Yes | (for analysts and institutional investors) |
(Amounts less than one million yen are rounded down)
1. Consolidated financial results for the year ended December 31, 2021 (from January 1, 2021 to December 31, 2021)
(1) Consolidated operating results | Percentages indicate year-on-year changes | ||||||||||||||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | ||||||||||||||||||
owners of parent | |||||||||||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | ||||||||||||||
Year ended December 31, 2021 | 414 | 16.5 | (171) | - | (159) | - | (148) | - | |||||||||||||
Year ended December 31, 2020 | 355 | (38.7) | (265) | - | (289) | - | (276) | - | |||||||||||||
Earnings per share | Diluted earnings per | Profit attributable to | Ordinary profit/total | Operating profit/net | |||||||||||||||||
share | owners of | assets | sales | ||||||||||||||||||
parent/equity | |||||||||||||||||||||
Yen | Yen | % | % | % | |||||||||||||||||
Year ended December 31, 2021 | (5.08) | - | - | (6.1) | (41.4) | ||||||||||||||||
Year ended December 31, 2020 | (10.16) | - | - | (12.3) | (74.7) | ||||||||||||||||
(2) Consolidated financial position | |||||||||||||||||||||
Total assets | Net assets | Equity ratio | Net assets per share | ||||||||||||||||||
Millions of yen | Millions of yen | % | Yen | ||||||||||||||||||
As of December 31, 2021 | 2,462 | 2,035 | 81.4 | 68.27 | |||||||||||||||||
As of December 31, 2020 | 2,737 | 2,163 | 78.9 | 73.88 | |||||||||||||||||
(3) Consolidated cash flows | |||||||||||||||||||||
Cash flows from | Cash flows from | Cash flows from | Cash and cash equivalents | ||||||||||||||||||
operating activities | investing activities | financing activities | at end of period | ||||||||||||||||||
Millions of yen | Millions of yen | Millions of yen | Millions of yen | ||||||||||||||||||
Year ended December 31, 2021 | (176) | (111) | (104) | 1,933 | |||||||||||||||||
Year ended December 31, 2020 | (216) | (13) | 1,004 | 2,308 | |||||||||||||||||
2. Cash dividends | |||||||||||||||||||||
Annual dividends per share | Total cash | Dividend payout | Ratio of dividends | ||||||||||||||||||
to net assets | |||||||||||||||||||||
1st quarter-end | 2nd quarter-end | 3rd quarter-end | Fiscal year-end | Total | dividends (Total) | ratio (Consolidated) | (Consolidated) | ||||||||||||||
Yen | Yen | Yen | Yen | Yen | Millions of yen | % | % | ||||||||||||||
Year ended December 31, 2020 | - | 0.00 | - | 0.00 | 0.00 | - | - | - | |||||||||||||
Year ended December 31, 2021 | - | 0.00 | - | 0.00 | 0.00 | - | - | - | |||||||||||||
Year ending December 31, 2022 | - | 0.00 | - | 0.00 | 0.00 | - | |||||||||||||||
(Forecast) | |||||||||||||||||||||
1
3. Forecast of consolidated financial results for the year ending December 31, 2022 (from January 1, 2022 to December 31, 2022)
Percentages indicate year-on-year changes
Net sales | Operating profit | Ordinary profit | Profit attributable to | Earnings per share | |||||||||
owners of parent | |||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | |||||
Full year | 370 | (10.7) | (690) | - | (700) | - | (670) | - | (22.82) | ||||
4. Notes | |||||||||||||
(1) Changes in significant subsidiaries during the year ended December 31, 2021 | No | ||||||||||||
(changes in specified subsidiaries resulting in the change in scope of consolidation): | |||||||||||||
(2) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements | |||||||||||||
Changes in accounting policies due to revisions to accounting standards and other regulations: | No | ||||||||||||
Changes in accounting policies due to other reasons: | No | ||||||||||||
Changes in accounting estimates: | No | ||||||||||||
Restatement of prior period financial statements: | No |
(3) Number of issued shares (common shares)
Total number of issued shares at the end of the period (including treasury shares)
As of December 31, 2021 | 29,358,600 | shares | As of December 31, 2020 | 29,251,100 | shares | |
Number of treasury shares at the end of the period | ||||||
As of December 31, 2021 | 100 | shares | As of December 31, 2020 | 100 | shares | |
Average number of shares during the period | ||||||
Year ended December 31, 2021 | 29,333,698 | shares | Year ended December 31, 2020 | 27,171,914 | shares |
2
Consolidated financial statements
Consolidated balance sheets
(Thousands of yen) | |||
As of December 31, 2020 | As of December 31, 2021 | ||
Assets | |||
Current assets | |||
Cash and deposits | 2,308,210 | 1,933,743 | |
Accounts receivable - trade | 91,877 | 101,674 | |
Supplies | 58,324 | 88,399 | |
Other | 44,872 | 38,365 | |
Total current assets | |||
2,503,284 | 2,162,183 | ||
Non-current assets | |||
Property, plant and equipment | |||
Buildings | 5,653 | 5,653 | |
Accumulated depreciation | (4,547) | (4,763) | |
Buildings, net | 1,105 | 889 | |
Tools, furniture and fixtures | 89,966 | 90,687 | |
Accumulated depreciation | (85,780) | (87,008) | |
Tools, furniture and fixtures, net | |||
4,186 | 3,678 | ||
Total property, plant and equipment | 5,292 | 4,567 | |
Intangible assets | |||
Contract-related intangible assets | 205,714 | 164,571 | |
Other | 2,540 | 2,047 | |
Total intangible assets | 208,254 | 166,619 | |
Investments and other assets | |||
Investment securities | 12,992 | 122,513 | |
Other | 7,887 | 6,975 | |
Total investments and other assets | 20,879 | 129,489 | |
Total non-current assets | 234,426 | 300,676 | |
Total assets | |||
2,737,711 | 2,462,860 | ||
Liabilities | |||
Current liabilities | |||
Current portion of long-term borrowings | 120,000 | 129,524 | |
Accounts payable - other | 37,637 | 41,759 | |
Income taxes payable | 18,771 | 9,889 | |
Other | 33,396 | 12,072 | |
Total current liabilities | 209,805 | 193,245 | |
Non-current liabilities | |||
Long-term borrowings | 340,000 | 210,476 | |
Other | 24,000 | 24,000 | |
Total non-current liabilities | 364,000 | 234,476 | |
Total liabilities | 573,805 | 427,721 | |
Net assets | |||
Shareholders' equity | |||
Share capital | 556,856 | 573,159 | |
Capital surplus | 2,655,571 | 2,631,398 | |
Retained earnings | (1,051,280) | (1,200,276) | |
Total shareholders' equity | 2,161,147 | 2,004,281 | |
Share acquisition rights | |||
2,758 | 2,692 | ||
Non-controlling interests | - | 28,164 | |
Total net assets | 2,163,905 | 2,035,138 | |
Total liabilities and net assets | |||
2,737,711 | 2,462,860 | ||
3
Consolidated statements of income and consolidated statements of comprehensive income Consolidated statements of income
(Thousands of yen) | |||
Fiscal year ended | Fiscal year ended | ||
December 31, 2020 | December 31, 2021 | ||
Net sales | 355,586 | 414,424 | |
Cost of sales | 17,019 | 20,099 | |
Gross profit | 338,566 | 394,324 | |
Selling, general and administrative expenses | |||
Research and development expenses | 350,535 | 316,161 | |
Other | 253,710 | 249,812 | |
Total selling, general and administrative expenses | 604,246 | 565,974 | |
Operating loss | (265,679) | (171,649) | |
Non-operating income | |||
Interest income | 127 | 21 | |
Foreign exchange gains | - | 17,382 | |
Other | 2,483 | 397 | |
Total non-operating income | 2,611 | 17,801 | |
Non-operating expenses | |||
Interest expenses | 4,728 | 4,424 | |
Foreign exchange losses | 6,334 | - | |
Share issuance costs | 3,666 | 1,168 | |
Share issuance costs | 5,535 | - | |
Other | 6,193 | 270 | |
Total non-operating expenses | 26,459 | 5,863 | |
Ordinary loss | (289,527) | (159,711) | |
Loss before income taxes | (289,527) | (159,711) | |
Income taxes - current | 1,595 | 1,595 | |
Total income taxes | 1,595 | 1,595 | |
Loss | (291,123) | (161,306) | |
Loss attributable to non-controlling interests | (15,018) | (12,311) | |
Loss attributable to owners of parent | (276,104) | (148,995) |
4
Consolidated statements of comprehensive income
(Thousands of yen) | ||
Fiscal year ended | Fiscal year ended | |
December 31, 2020 | December 31, 2021 | |
Loss | (291,123) | (161,306) |
Comprehensive income | (291,123) | (161,306) |
Comprehensive income attributable to | ||
Comprehensive income attributable to owners of parent | (276,104) | (148,995) |
Comprehensive income attributable to non-controlling | (15,018) | (12,311) |
interests | ||
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
D.Western Therapeutics Institute Inc. published this content on 14 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 February 2022 06:52:08 UTC.
